{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T12:11:36Z","timestamp":1794658296702,"version":"4.9.1"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Population Health Research Institute and the Department of Medicine at McMaster University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60216-3","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:27:44Z","timestamp":1749101264000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["No evidence of immune exhaustion after repeated SARS-CoV-2 vaccination in vulnerable and healthy populations"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8767-933X","authenticated-orcid":false,"given":"Jenna M.","family":"Benoit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5434-9158","authenticated-orcid":false,"given":"Jessica A.","family":"Breznik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5313-5724","authenticated-orcid":false,"given":"Braeden","family":"Cowbrough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Hagerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine M.","family":"Andary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Mushtaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Abdalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3650-3506","authenticated-orcid":false,"given":"Jamie D.","family":"McNicol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Gauvreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0504-3064","authenticated-orcid":false,"given":"Paul Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judah A.","family":"Denburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl P.","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishac","family":"Nazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MyLinh","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2874-6886","authenticated-orcid":false,"given":"Jonathan L.","family":"Bramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie J.","family":"Larch\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris P.","family":"Verschoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6823-2957","authenticated-orcid":false,"given":"Dawn M. E.","family":"Bowdish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"60216_CR1","unstructured":"Canada, P. H. A. of COVID-19 vaccines: Canadian Immunization Guide. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-26-covid-19-vaccine.html (2021)."},{"key":"60216_CR2","unstructured":"Clinical Guidance for COVID-19 Vaccination. CDC https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html (2024)."},{"key":"60216_CR3","doi-asserted-by":"crossref","unstructured":"Kriss, J. L. COVID-19 vaccine second-dose completion and interval between first and second doses among vaccinated persons \u2014 United States, December 14, 2020\u2212February 14, 2021. MMWR Morb. Mortal Wkly. Rep. 70, 389\u2013395 (2021).","DOI":"10.15585\/mmwr.mm7011e2"},{"key":"60216_CR4","unstructured":"Canada, P. H. A. of. COVID-19 vaccine doses administered \u2014 Canada.ca. aem https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-administration\/#a3 (2021)."},{"key":"60216_CR5","unstructured":"Canada, P. H. A. of. Guidance on the use of COVID-19 vaccines during the fall of 2024. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/vaccines-immunization\/national-advisory-committee-immunization-guidance-covid-19-vaccines-fall-2024.html (2024)."},{"key":"60216_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.17269\/s41997-024-00885-7","volume":"115","author":"B Manoharan","year":"2024","unstructured":"Manoharan, B. et al. Sociodemographic factors associated with vaccine hesitancy in the South Asian community in Canada. Can. J. Public Health 115, 924\u2013935 (2024).","journal-title":"Can. J. Public Health"},{"key":"60216_CR7","unstructured":"Hamel, L. et al. KFF COVID-19 Vaccine Monitor: October 2021. KFF https:\/\/www.kff.org\/coronavirus-covid-19\/poll-finding\/kff-covid-19-vaccine-monitor-october-2021\/ (2021)."},{"key":"60216_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17292-4","volume":"11","author":"S De Biasi","year":"2020","unstructured":"De Biasi, S. et al. Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia. Nat. Commun. 11, 3434 (2020).","journal-title":"Nat. Commun."},{"key":"60216_CR9","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1111\/all.14866","volume":"76","author":"S Adamo","year":"2021","unstructured":"Adamo, S. et al. Profound dysregulation of T cell homeostasis and function in patients with severe COVID-19. Allergy 76, 2866\u20132881 (2021).","journal-title":"Allergy"},{"key":"60216_CR10","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1111\/j.1365-2567.2010.03255.x","volume":"129","author":"JS Yi","year":"2010","unstructured":"Yi, J. S., Cox, M. A. & Zajac, A. J. T-cell exhaustion: characteristics, causes and conversion. Immunology 129, 474\u2013481 (2010).","journal-title":"Immunology"},{"key":"60216_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","volume":"19","author":"CU Blank","year":"2019","unstructured":"Blank, C. U. et al. Defining \u2018T cell exhaustion. Nat. Rev. Immunol. 19, 665\u2013674 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"60216_CR12","first-page":"2431","volume":"196","author":"APR Bally","year":"2016","unstructured":"Bally, A. P. R., Austin, J. W. & Boss, J. M. Genetic and epigenetic regulation of PD-1 expression. J. I. 196, 2431\u20132437 (2016).","journal-title":"J. I."},{"key":"60216_CR13","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1038\/s41423-021-00750-4","volume":"18","author":"M-S Rha","year":"2021","unstructured":"Rha, M.-S. & Shin, E.-C. Activation or exhaustion of CD8+ T cells in patients with COVID-19. Cell Mol. Immunol. 18, 2325\u20132333 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"60216_CR14","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.immuni.2020.12.002","volume":"54","author":"M-S Rha","year":"2021","unstructured":"Rha, M.-S. et al. PD-1-expressing SARS-CoV-2-specific CD8+ T cells are not exhausted, but functional in patients with COVID-19. Immunity 54, 44\u201352.e3 (2021).","journal-title":"Immunity"},{"key":"60216_CR15","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nbt.3187","volume":"33","author":"L Lin","year":"2015","unstructured":"Lin, L. et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat. Biotechnol. 33, 610\u2013616 (2015).","journal-title":"Nat. Biotechnol."},{"key":"60216_CR16","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.coi.2012.04.001","volume":"24","author":"SM Henson","year":"2012","unstructured":"Henson, S. M., Riddell, N. E. & Akbar, A. N. Properties of end-stage human T cells defined by CD45RA re-expression. Curr. Opin. Immunol. 24, 476\u2013481 (2012).","journal-title":"Curr. Opin. Immunol."},{"key":"60216_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.it.2009.03.013","volume":"30","author":"N Weng","year":"2009","unstructured":"Weng, N., Akbar, A. N. & Goronzy, J. CD28\u2212 T cells: their role in the age-associated decline of immune function. Trends Immunol. 30, 306\u2013312 (2009).","journal-title":"Trends Immunol."},{"key":"60216_CR18","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","volume":"101","author":"JM Brenchley","year":"2003","unstructured":"Brenchley, J. M. et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 101, 2711\u20132720 (2003).","journal-title":"Blood"},{"key":"60216_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/j.1365-2567.2011.03470.x","volume":"134","author":"M Strioga","year":"2011","unstructured":"Strioga, M., Pasukoniene, V. & Characiejus, D. CD8+ CD28- and CD8+ CD57+ T cells and their role in health and disease. Immunology 134, 17\u201332 (2011).","journal-title":"Immunology"},{"key":"60216_CR20","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.cell.2022.01.018","volume":"185","author":"K R\u00f6ltgen","year":"2022","unstructured":"R\u00f6ltgen, K. et al. Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. Cell 185, 1025 (2022).","journal-title":"Cell"},{"key":"60216_CR21","doi-asserted-by":"crossref","unstructured":"Quach, C. & Deeks, S. COVID-19 vaccination: Why extend the interval between doses? J. Assoc. Med. Microbiol. Infect. Dis. Can. 6, 73\u201378 (2021).","DOI":"10.3138\/jammi-2021-0323"},{"key":"60216_CR22","doi-asserted-by":"publisher","first-page":"e0281673","DOI":"10.1371\/journal.pone.0281673","volume":"18","author":"DP Leong","year":"2023","unstructured":"Leong, D. P. et al. Comparison of three dosing intervals for the primary vaccination of the SARS-CoV-2 mRNA Vaccine (BNT162b2) on magnitude, neutralization capacity and durability of the humoral immune response in health care workers: a prospective cohort study. PLoS ONE 18, e0281673 (2023).","journal-title":"PLoS ONE"},{"key":"60216_CR23","doi-asserted-by":"publisher","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","volume":"184","author":"RP Payne","year":"2021","unstructured":"Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell 184, 5699\u20135714.e11 (2021).","journal-title":"Cell"},{"key":"60216_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adh0687","volume":"8","author":"C Cai","year":"2023","unstructured":"Cai, C. et al. SARS-CoV-2 vaccination enhances the effector qualities of spike-specific T cells induced by COVID-19. Sci. Immunol. 8, eadh0687 (2023).","journal-title":"Sci. Immunol."},{"key":"60216_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add3899","volume":"7","author":"Y Maringer","year":"2022","unstructured":"Maringer, Y. et al. Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. Sci. Immunol. 7, eadd3899 (2022).","journal-title":"Sci. Immunol."},{"key":"60216_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.20411\/pai.v8i1.613","volume":"8","author":"S Datwani","year":"2023","unstructured":"Datwani, S. et al. Dynamics of T-cell responses following COVID-19 mRNA vaccination and breakthrough infection in older adults. Pathog. Immun. 8, 117\u2013135 (2023).","journal-title":"Pathog. Immun."},{"key":"60216_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32324-x","volume":"13","author":"M Reinscheid","year":"2022","unstructured":"Reinscheid, M. et al. COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation. Nat. Commun. 13, 4631 (2022).","journal-title":"Nat. Commun."},{"key":"60216_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50263-5","volume":"13","author":"JM Benoit","year":"2023","unstructured":"Benoit, J. M. et al. Immunomodulatory drugs have divergent effects on humoral and cellular immune responses to SARS-CoV-2 vaccination in people living with rheumatoid arthritis. Sci. Rep. 13, 22846 (2023).","journal-title":"Sci. Rep."},{"key":"60216_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijid.2022.10.035","volume":"125","author":"C Farroni","year":"2022","unstructured":"Farroni, C. et al. Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: a prospective multicenter longitudinal study. Int. J. Infect. Dis. 125, 195\u2013208 (2022).","journal-title":"Int. J. Infect. Dis."},{"key":"60216_CR30","doi-asserted-by":"crossref","unstructured":"Swanson, P. A. et al. AZD1222\/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein\u2013specific TH1 response with a diverse TCR repertoire. Sci. Transl. Med. 13, eabj7211 (2021).","DOI":"10.1126\/scitranslmed.abj7211"},{"key":"60216_CR31","doi-asserted-by":"crossref","unstructured":"Li, L. et al. In-depth analysis of SARS-CoV-2\u2013specific T cells reveals diverse differentiation hierarchies in vaccinated individuals. JCI Insight 7, e156559 (2022).","DOI":"10.1172\/jci.insight.156559"},{"key":"60216_CR32","doi-asserted-by":"crossref","unstructured":"Loretelli, C. et al. PD-1 blockade counteracts post\u2013COVID-19 immune abnormalities and stimulates the anti\u2013SARS-CoV-2 immune response. JCI Insight 6, e146701 (2021).","DOI":"10.1172\/jci.insight.146701"},{"key":"60216_CR33","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/s41590-022-01184-4","volume":"23","author":"AA Minervina","year":"2022","unstructured":"Minervina, A. A. et al. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells. Nat. Immunol. 23, 781\u2013790 (2022).","journal-title":"Nat. Immunol."},{"key":"60216_CR34","doi-asserted-by":"crossref","unstructured":"Kavazovi\u0107, I. et al. Vaccination provides superior in vivo recall capacity of SARS-CoV-2-specific memory CD8 T cells. Cell Reports 42, (2023).","DOI":"10.1016\/j.celrep.2023.112395"},{"key":"60216_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl5344","volume":"6","author":"G Guerrera","year":"2021","unstructured":"Guerrera, G. et al. BNT162b2 vaccination induces durable SARS-CoV-2\u2013specific T cells with a stem cell memory phenotype. Sci. Immunol. 6, eabl5344 (2021).","journal-title":"Sci. Immunol."},{"key":"60216_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012526","volume":"13","author":"FG \u00d6zbay Kurt","year":"2022","unstructured":"\u00d6zbay Kurt, F. G. et al. Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. Front. Immunol. 13, 1012526 (2022).","journal-title":"Front. Immunol."},{"key":"60216_CR37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202780119","volume":"119","author":"ET Klopack","year":"2022","unstructured":"Klopack, E. T., Crimmins, E. M., Cole, S. W., Seeman, T. E. & Carroll, J. E. Social stressors associated with age-related T lymphocyte percentages in older US adults: evidence from the US Health and Retirement Study. Proc. Natl. Acad. Sci. USA 119, e2202780119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60216_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/jgs.14507","volume":"65","author":"J Johnstone","year":"2017","unstructured":"Johnstone, J. et al. T-cell phenotypes predictive of frailty and mortality in elderly nursing home residents. J. Am. Geriatrics Soc. 65, 153\u2013159 (2017).","journal-title":"J. Am. Geriatrics Soc."},{"key":"60216_CR39","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/s43587-022-00198-9","volume":"2","author":"OJ Luo","year":"2022","unstructured":"Luo, O. J. et al. Multidimensional single-cell analysis of human peripheral blood reveals characteristic features of the immune system landscape in aging and frailty. Nat. Aging 2, 348\u2013364 (2022).","journal-title":"Nat. Aging"},{"key":"60216_CR40","doi-asserted-by":"crossref","unstructured":"Castro-Herrera, V. M. et al. Relationships between age, frailty, length of care home residence and biomarkers of immunity and inflammation in older care home residents in the United Kingdom. Front. Aging 2, 599084 (2021).","DOI":"10.3389\/fragi.2021.599084"},{"key":"60216_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12877-022-03101-8","volume":"22","author":"R Milte","year":"2022","unstructured":"Milte, R. et al. Prevalence and determinants of physical frailty among people living in residential aged care facilities: a large-scale retrospective audit. BMC Geriatrics 22, 424 (2022).","journal-title":"BMC Geriatrics"},{"key":"60216_CR42","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1001\/jama.2020.12839","volume":"324","author":"WJ Wiersinga","year":"2020","unstructured":"Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J. & Prescott, H. C. Pathophysiology, transmission, diagnosis, and treatment of Coronavirus Disease 2019 (COVID-19): a review. JAMA 324, 782\u2013793 (2020).","journal-title":"JAMA"},{"key":"60216_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.idc.2022.11.001","volume":"37","author":"Y Abul","year":"2023","unstructured":"Abul, Y., Leeder, C. & Gravenstein, S. Epidemiology and clinical presentation of COVID-19 in older adults. Infect. Dis. Clin. North Am. 37, 1\u201326 (2023).","journal-title":"Infect. Dis. Clin. North Am."},{"key":"60216_CR44","doi-asserted-by":"publisher","first-page":"e765","DOI":"10.1016\/S2665-9913(22)00227-2","volume":"4","author":"G Figueroa-Parra","year":"2022","unstructured":"Figueroa-Parra, G. et al. Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study. Lancet Rheumatol. 4, e765\u2013e774 (2022).","journal-title":"Lancet Rheumatol."},{"key":"60216_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-024-00431-5","volume":"8","author":"L Jin","year":"2024","unstructured":"Jin, L. et al. Rheumatoid arthritis and COVID-19 outcomes: a systematic review and Meta-analysis. BMC Rheumatol. 8, 61 (2024).","journal-title":"BMC Rheumatol."},{"key":"60216_CR46","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/s41584-022-00755-x","volume":"18","author":"R Grainger","year":"2022","unstructured":"Grainger, R., Kim, A. H. J., Conway, R., Yazdany, J. & Robinson, P. C. COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. Nat. Rev. Rheumatol. 18, 191\u2013204 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"60216_CR47","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/lifemedi\/lnac013","volume":"1","author":"SX Leng","year":"2022","unstructured":"Leng, S. X. & Pawelec, G. Single-cell immune atlas for human aging and frailty. Life Med. 1, 67\u201370 (2022).","journal-title":"Life Med"},{"key":"60216_CR48","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41590-021-01126-6","volume":"23","author":"VG Hall","year":"2022","unstructured":"Hall, V. G. et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat. Immunol. 23, 380\u2013385 (2022).","journal-title":"Nat. Immunol."},{"key":"60216_CR49","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nri2274","volume":"8","author":"RA Seder","year":"2008","unstructured":"Seder, R. A., Darrah, P. A. & Roederer, M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8, 247\u2013258 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"60216_CR50","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/nm1592","volume":"13","author":"PA Darrah","year":"2007","unstructured":"Darrah, P. A. et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843\u2013850 (2007).","journal-title":"Nat. Med"},{"key":"60216_CR51","unstructured":"Canada, P. H. A. of. Rapid review on protective immunity post infection with SARS-CoV-2: update 3. https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/2019-novel-coronavirus-infection\/canadas-reponse\/summaries-recent-evidence\/rapid-review-protective-immunity-post-infection-sars-cov-2-update-3.html (2022)."},{"key":"60216_CR52","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.4049\/jimmunol.0803548","volume":"183","author":"JJ Zaunders","year":"2009","unstructured":"Zaunders, J. J. et al. High levels of human antigen-specific CD4+ T cells in peripheral blood revealed by stimulated coexpression of CD25 and CD134 (OX40). J. Immunol. 183, 2827\u20132836 (2009).","journal-title":"J. Immunol."},{"key":"60216_CR53","doi-asserted-by":"publisher","first-page":"e0186998","DOI":"10.1371\/journal.pone.0186998","volume":"12","author":"S Reiss","year":"2017","unstructured":"Reiss, S. et al. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS ONE 12, e0186998 (2017).","journal-title":"PLoS ONE"},{"key":"60216_CR54","doi-asserted-by":"publisher","first-page":"916","DOI":"10.4049\/jimmunol.2200638","volume":"210","author":"NX Nguyen","year":"2023","unstructured":"Nguyen, N. X. et al. Immunogen-specific strengths and limitations of the activation-induced marker assay for assessing murine antigen-specific CD4+ T cell responses. J. Immunol. 210, 916\u2013925 (2023).","journal-title":"J. Immunol."},{"key":"60216_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29170","volume":"95","author":"JA Breznik","year":"2023","unstructured":"Breznik, J. A. et al. Early humoral and cellular responses after bivalent SARS-CoV-2 mRNA-1273.214 vaccination in long-term care and retirement home residents in Ontario, Canada: an observational cohort study. J. Med. Virol. 95, e29170 (2023).","journal-title":"J. Med. Virol."},{"key":"60216_CR56","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1093\/ageing\/afab006","volume":"50","author":"O Theou","year":"2021","unstructured":"Theou, O. et al. A classification tree to assist with routine scoring of the Clinical Frailty Scale. Age Ageing 50, 1406\u20131411 (2021).","journal-title":"Age Ageing"},{"key":"60216_CR57","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.jamda.2023.12.013","volume":"25","author":"Z Pasat","year":"2024","unstructured":"Pasat, Z. et al. Examining the association between frailty and antibody neutralization of SARS-CoV-2: a multisite retrospective cohort study. J. Am. Med. Dir. Assoc. 25, 647\u2013649.e8 (2024).","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"60216_CR58","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1111\/jgs.17299","volume":"69","author":"F Dumitrascu","year":"2021","unstructured":"Dumitrascu, F., Branje, K. E., Hladkowicz, E. S., Lalu, M. & McIsaac, D. I. Association of frailty with outcomes in individuals with COVID-19: a living review and meta-analysis. J. Am. Geriatrics Soc. 69, 2419\u20132429 (2021).","journal-title":"J. Am. Geriatrics Soc."},{"key":"60216_CR59","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/vaccines12091061","volume":"12","author":"CA Hitchon","year":"2024","unstructured":"Hitchon, C. A. et al. Methotrexate and tumor necrosis factor inhibitors independently decrease neutralizing antibodies after SARS-CoV-2 vaccination: updated results from the SUCCEED study. Vaccines (Basel) 12, 1061 (2024).","journal-title":"Vaccines (Basel)"},{"key":"60216_CR60","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.4049\/jimmunol.2200369","volume":"209","author":"JA Breznik","year":"2022","unstructured":"Breznik, J. A. et al. Cytomegalovirus seropositivity in older adults changes the T cell repertoire but does not prevent antibody or cellular responses to SARS-CoV-2 vaccination. J. Immunol. 209, 1892\u20131905 (2022).","journal-title":"J. Immunol."},{"key":"60216_CR61","doi-asserted-by":"crossref","unstructured":"Jubel, J. M., Barbati, Z. R., Burger, C., Wirtz, D. C. & Schildberg, F. A. The role of PD-1 in acute and chronic infection. Front. Immunol. 11, 487 (2020).","DOI":"10.3389\/fimmu.2020.00487"},{"key":"60216_CR62","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1002\/eji.200737857","volume":"38","author":"DA Hokey","year":"2008","unstructured":"Hokey, D. A. et al. Activation drives PD-1 expression during vaccine-specific proliferation and following lentiviral infection in macaques. Eur. J. Immunol. 38, 1435\u20131445 (2008).","journal-title":"Eur. J. Immunol."},{"key":"60216_CR63","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3390\/v13112239","volume":"13","author":"AE Kennedy","year":"2021","unstructured":"Kennedy, A. E. et al. Lasting changes to circulating leukocytes in people with mild SARS-CoV-2 infections. Viruses 13, 2239 (2021).","journal-title":"Viruses"},{"key":"60216_CR64","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.cell.2020.08.017","volume":"183","author":"T Sekine","year":"2020","unstructured":"Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183, 158\u2013168.e14 (2020).","journal-title":"Cell"},{"key":"60216_CR65","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","volume":"185","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847\u2013859.e11 (2022).","journal-title":"Cell"},{"key":"60216_CR66","doi-asserted-by":"publisher","unstructured":"Verschoor, C. COMPASS analysis to investigate immune exhaustion. https:\/\/doi.org\/10.5281\/zenodo.15329735 (Zenodo, 2025).","DOI":"10.5281\/zenodo.15329735"}],"updated-by":[{"DOI":"10.1038\/s41467-025-61098-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60216-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T03:01:56Z","timestamp":1750388516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60216-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60216"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60216-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5485352\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-025-61098-1","URL":"https:\/\/doi.org\/10.1038\/s41467-025-61098-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.L. is the Director of the Canadian Scleroderma Research Group and has received honoraria for consulting or speakers fees from AbbVie, Actelion, Amgen, AstraZeneca, Boehringer-Ingelheim, BMS, Fresenius-Kabi, GSK, Lilly, Mallinckrodt, Novartis, Pfizer, Sanofi, SOBI, UCB, and Scleroderma Society of Ontario\/Canada. D.M.E.B. has received honorarium from Pfizer-Global, Pfizer Canada, and AstraZeneca for consulting on the topics of vaccines. D.M.E.B. is on the Board of Directors of the Lung Health Foundation (unpaid, volunteer), and speaks on the topic of adult vaccination and other lung health issues to policymakers, knowledge users, and the general public. D.M.E.B. was an expert witness for the below court cases on the topic of vaccination; (i) Nabil Ben Naoum vs. L\u2019honorable Maxime Bernier, Canada. Provided written affidavit. and was cross examined. June-September, 2022. (ii) David Lavergne-Poitras vs. PMG Technologies Inc., Canada, Montreal, QC. Provided written affidavit. and was cross examined. May-July 2022. (iii) Syndicat des Metallos S.L., 2008, 9599, 2004, 9344, 9554, 1976, 9449, 9519, 5778, 9996 et als. vs. Procureur General du Canada, Canada, Montreal, QC. Provided written affidavit. March-May 2022. (iv) Fisman et al ats Bridle.DM-LSDOCS.FID1093293. Provided written affidavit. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5219"}}